Denali Therapeutics IPO

12/7/2017

IPO

$250,200,000

We currently anticipate that we will use the net proceeds from this offering, together with our existing resources, through 2019 as follows: approximately $20 to $25 million to fund the costs of Phase 1 trials in healthy volunteers for each of DNL201 and DNL151 and a Phase 1b study in LRRK2 mutation-carrying Parkinson's disease patients, as well as preparation for a potential future Phase 2 clinical trial; approximately $30 to $35 million to fund the costs to advance our RIPK1 program through Phase 1 and early Phase 2 clinical development, substantially represented by the planned Phase 1 clinical trial in healthy volunteers, including a cohort in Alzheimer's disease patients, for DNL747 and a Phase 2a clinical trial in ALS patients and a Phase 2a clinical trial in Alzheimer's disease patients; approximately $45 to $50 million to optimize and broaden our ATV and ETV platform technologies and to advance our four core antibody and enzyme replacement programs through preclinical developmen

Publicly-held

Biopharmaceutical

161 Oyster Point Blvd.
San Francisco, CA 94080
USA

Undisclosed

Denali (NASDAQ: DNLI) was founded on the collaboration of leading scientists, industry experts and investors who share the vision that scientific discovery energetically applied to translational medicine is the key to delivering effective therapies to patients.